Loading
Tumours recruit nerves and use nerve signals to grow. Blocking that traffic, with beta-blockers or botulinum toxin, is being tested.
Nerves infiltrate tumours and drive proliferation through adrenergic and cholinergic signalling; perineural invasion is a long-standing prognostic marker. Trials are testing perioperative propranolol in prostate cancer (NCT05679193, completed), pancreatic cancer (NCT06145074, recruiting), and beta-blockade with a COX-2 inhibitor in ovarian cancer (NCT06839144, recruiting). Botulinum toxin denervation has been trialled in gastric cancer. Effects so far are on biomarkers, not survival.
Adrenergic and cholinergic nerve endings supply growth and survival signals to tumour and stromal cells; pharmacological or surgical denervation removes them.
Query for this technology: (TITLE:"Cancer neuroscience: cutting the nerve supply" OR ABSTRACT:"Cancer neuroscience: cutting the nerve supply") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cancer neuroscience: cutting the nerve supply, not a curated reading list.
Shares Cardio-oncology and the tags frontier, radical.
Shares Pancreatic ductal adenocarcinoma and the tags frontier, radical.
Shares Pancreatic ductal adenocarcinoma and the tags frontier, radical.
Shares Pancreatic ductal adenocarcinoma and the tags frontier, radical.
Shares the tags frontier, radical.
Shares the tags frontier, radical.
Shares the tags frontier, radical.
Shares the tags frontier, radical.